US FDA delays Sanofi-Aventis's sleeping pill with complete response letter
This article was originally published in Scrip
Executive Summary
The US FDA has issued Sanofi-Aventis a complete response letter for its chronic insomnia drug Ciltyri (eplivanserin), requesting further information on the drug's benefit-risk profile.